Plerixafor
Mozobil (plerixafor) is a brand-name medication used as a stem cell mobilizer in adults with certain cancers who need to collect stem cells for transplantation. It works by helping move stem cells from the bone marrow into the bloodstream so they can be collected. It is typically used together with a growth factor called G-CSF in patients with non-Hodgkin's lymphoma or multiple myeloma.
Mozobil is a stem cell mobilizer used to help collect blood stem cells from cancer patients for transplantation.
Key facts at a glance
- RxNorm
- 735381
- Generic
- Mozobil
- Class
- brand-name
- Brands
- —
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Mozobil is indicated for hematopoietic stem cell mobilization and collection in patients with non-Hodgkin's lymphoma and multiple myeloma prior to autologous transplantation. It is used in combination with granulocyte colony-stimulating factor (G-CSF) when stem cell collection is inadequate with G-CSF alone.
Mozobil is a selective antagonist of the CXCR4 chemokine receptor. It blocks the interaction between CXCR4 and its ligand SDF-1 (stromal cell-derived factor-1), which normally keeps stem cells anchored in the bone marrow. By disrupting this interaction, Mozobil causes stem cells to detach and circulate into the peripheral blood, where they can be collected via apheresis.
Mozobil is administered by subcutaneous injection, typically in the evening before each apheresis session. Common side effects may include injection site reactions, gastrointestinal symptoms, and headache. It should be used under the supervision of a physician experienced in oncology or hematology. Patients should be monitored for potential spleen enlargement and blood count changes during treatment.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy